{"disease":{"id":"transplant-glomerulopathy","name":"transplant glomerulopathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03380962","title":"Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Stanley Jordan, MD","has_results":false},{"nct_id":"NCT03380377","title":"Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Stanley Jordan, MD","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}